What 500 Ingredients Taught Us About Formulation

After cataloging 500+ functional and nutraceutical ingredients across our portfolio, the patterns that surfaced changed how we think about what actually belongs in a finished product.

Most “innovation” is rebranding

The functional category spits out hundreds of “new” ingredients a year. The honest count of genuinely novel actives — new molecules, new clinical mechanisms, new extraction technology — is far smaller. A meaningful share of what shows up at trade shows is the same compound, sourced from a different supplier, wearing a different trademark.



Which means the strategic question for formulators isn’t “What new ingredient should we use?” It’s “Which version of a given ingredient is worth paying for — and why?”

The branded ingredients earning their premium right now are the ones with multiple human clinical studies behind them. Everything else is closer to commodity than the marketing suggests.

Adherence beats novelty — every time

We’ve watched formulations with mediocre actives outperform those built on state-of-the-art actives, for one simple reason: the first was easier to take.

The category has spent two decades chasing potency. We think the next decade belongs to whoever designs for follow-through. An ingredient that delivers 70% of the clinical effect, taken 90% of the time, beats an ingredient that delivers 100% of the effect taken 40% of the time. The math isn’t close.



That flips ingredient selection on its head. The best active for a daily wellness product isn’t necessarily the most-studied one. It’s the one best suited to the format, dose, and routine the average consumer will actually follow.

The “clinically studied” pool is smaller than it looks

Walk any supplement trade show and every booth seems to have clinical data. Read the actual studies, though, and the picture changes. A surprising share of “clinically studied” actives rest on one small trial — often industry-sponsored, often using a different dose or form than what ends up in the finished product.

So “clinically studied” is a spectrum, not a binary. Formulators who treat it as a checkbox are doing their consumers a disservice.

At Step Change, if an ingredient has fewer than three independent human studies, we describe it accordingly. If it has more, we say so. That’s the whole point of the work.

The next wave isn’t ingredients — it’s systems

The most interesting work coming out of the catalog isn’t about single actives. It’s about combinations designed to work together:

• Synbiotic systems that pair probiotics with the prebiotics that feed them.
• Adaptogen stacks with components targeting different stress pathways.
• Bioavailability platforms that change how an active is absorbed.

These products are harder to copy and easier to defend. A single novel ingredient can be reverse-engineered or swapped out. A formulation system — where the ratio, the form, and the delivery technology all matter — sits on far higher ground.

That’s why our Calmology™ blend isn’t about one stress ingredient; it’s about a specific combination performing across a defined stress profile. Our Quad Seed Protein™ offering isn’t about one seed; it’s about why those four together produce a more complete amino acid profile than any one alone.

The IP isn’t the ingredient. It’s the architecture. The category’s next decade of margin will live here.

Regulatory clarity is the underrated competitive advantage

Boring, perhaps, but true. After 500+ ingredients, the single most underestimated variable we see is regulatory status. Is it GRAS? In which countries is it allowed? At what dose? With what claims? Get this wrong and your launch dies slowly, expensively, and right before it was scheduled to scale.

The ingredients that actually win at retail aren’t always the ones with the strongest clinical story. They’re the ones with the cleanest regulatory profile, the clearest claim path, and documentation a buyer can hand to their legal team without breaking a sweat. Serious companies treat regulatory work as core, not as cleanup. The ones who don’t tend to hit a wall in year two.

What this means for the category

The functional category isn’t a race for the next novel active. These five observations point to something closer to a discipline: selecting the right known actives, in the right systems, at doses that get taken, with regulatory documentation that holds up.

The companies that build that discipline end up with portfolios that survive contact with real consumers. The companies chasing novelty for its own sake keep launching into the same wall.

The Step Change view

The catalog isn’t the product. It’s the proving ground for the product. 500+ ingredients sounds like a lot — until you run them through real adherence, regulatory, and clinical filters and see how few earn a spot in a finished SKU.

That’s why we built our platform the way we did — a control-brand model (Wellwerks and Nüwerks) on top of a deep ingredient-and-supplier network — so the right ingredient ends up in the right format in the right SKU.

The bottom line

After 500+ ingredients, the lesson isn’t that we found something new. It’s that the category has been looking in the wrong place.

The next wave of winners won’t be the brands with the most ingredients. They’ll be the brands that picked the right ones — and put them in formats people actually finish.